Hydrocortisoneacetatesuppository

Manufacturer
APNAR PHARMA LP
Effective date
2022-03-16
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-05-31 20:40:34

Label at a glance#

ProductHydrocortisone Acetate
Active ingredientHYDROCORTISONE ACETATE
Label structure17 sections

Indications and uses

Hydrocortisone acetate suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani.

Dosage and administration

FOR RECTAL ADMINISTRATION . Detach one suppository from strip of suppositories. Hold suppository upright and carefully separate tabs at top opening and pull downward from the pointed end to expose the suppository. Remove the suppository from the pocket. Avoid excessive handling of suppository which is designed to melt at body temperature. Insert one suppository rectally, pointed end first. Insert one suppository i...

Storage and handling

Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Excursions permitted to 15°- 30°C (59°-86°F). Store away from heat. Protect from freezing. Avoid contact with eyes. KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN . In case of accidental ingestion, seek professional assistance or contact a Poison Control Center immediately. PHARMACIST : This product is not an Orange Book rated product, there...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Hydrocortisone Acetate is a corticosteroid designated chemically as pregn-4-ene 3, 20-dione, 21- (acetyloxy)-11,17-dihydroxy-(11ß)
with the following structural formula:

structural formulastructural formula

Each rectal suppository contains hydrocortisone acetate, 25 mg in a specially blended hydrogenated vegetable oil base.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

In normal subjects, about 26% of hydrocortisone acetate is absorbed when the suppository is applied to the rectum. Absorption of hydrocortisone acetate may vary across abraded or inflamed surfaces. Topical steroids are primarily effective because of their anti- inflammatory, anti-pruritic and vasoconstrictive action.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Hydrocortisone acetate suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Hydrocortisone acetate suppositories are contraindicated in those patients having a history of hypersensitivity to hydrocortisone acetate or any of the components.

PRECAUTIONS

PRECAUTIONS SECTION

Do not use hydrocortisone acetate suppositories unless adequate proctologic examination is made. If irritation develops, the product should be discontinued and appropriate therapy instituted.

In the presence of an infection, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, hydrocortisone acetate should be discontinued until the infection has been adequately controlled.

Carcinogenesis

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No long term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories.

INFORMATION FOR PATIENTS

INFORMATION FOR PATIENTS SECTION

Staining of fabric may occur with use of the suppository. Precautionary measures are recommended.

PREGNANCY CATEGORY C

PREGNANCY SECTION

In laboratory animals, topical steroids have been associated with an increase in the incidence of fetal abnormalities when gestating females have been exposed to rather low dosage levels. There are no adequate and well controlled studies in pregnant women.

Hydrocortisone acetate suppositories should only be used during pregnancy if the potential benefit justifies the risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

It is not known whether this drug is excreted in human milk and because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydrocortisone acetate suppositories, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following local adverse reactions have been reported with hydrocortisone acetate suppositories: burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, secondary infection.

To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG ABUSE AND DEPENDENCE

DRUG ABUSE AND DEPENDENCE SECTION

Drug abuse and dependence have not been reported in patients treated with hydrocortisone acetate suppositories.

OVERDOSAGE

OVERDOSAGE SECTION

If signs and symptoms of systemic overdosage occur, discontinue use.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

FOR RECTAL ADMINISTRATION. Detach one suppository from strip of suppositories. Hold suppository upright and carefully separate tabs at top opening and pull downward from the pointed end to expose the suppository. Remove the suppository from the pocket. Avoid excessive handling of suppository which is designed to melt at body temperature. Insert one suppository rectally, pointed end first. Insert one suppository in the rectum twice daily, morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times a day or two suppositories twice daily. In factitial proctitis, the recommended duration of therapy is six to eight weeks or less, according to the response of the individual case.

HOW SUPPLIED

HOW SUPPLIED SECTION

Boxes of 12 suppositories NDC 24689-102-01

Boxes of 12 suppositories NDC 24689-103-01

STORAGE AND HANDLING

STORAGE AND HANDLING SECTION

Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Excursions permitted to 15°- 30°C (59°-86°F).

Store away from heat. Protect from freezing. Avoid contact with eyes.

KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN. In case of accidental ingestion, seek professional assistance or contact a Poison Control Center immediately.

PHARMACIST: This product is not an Orange Book rated product, therefore all prescriptions using this product shall be subject to state and federal statutes as applicable. This product has not been subjected to FDA therapeutic or other equivalency testing. There are no claims of bioequivalence or therapeutic equivalence. Each person recommending a prescription substitution using this product shall make such recommendation based on his/her professional knowledge and opinion, upon evaluating the active ingredients, inactive ingredients, excipients and chemical information contained within the enclosed prescribing information.

SPL UNCLASSIFIED SECTION

Rx Only

Manufactured for:

Apnar Pharma LP

CHINO, CA 91710

Rev. 08/21

25mg- Suppositories carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 24689-102-01


Rx Only

Hydrocortisone Acetate
Suppositories
25 mg

FOR RECTAL USE ONLY

APNAR PHARMA LP

12 Suppositories
Unit Dose

25mg-Suppositories Carton25mg-Suppositories Carton

30mg-Suppositories Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 24689-103-01


Rx Only

Hydrocortisone Acetate
Suppositories
30 mg

FOR RECTAL USE ONLY

APNAR PHARMA LP

12 Suppositories
Unit Dose

30mg-Suppositories carton30mg-Suppositories carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1291082hydrocortisone acetate 25 MG Rectal SuppositoryPSN2
1291085hydrocortisone acetate 30 MG Rectal SuppositoryPSN2
1291082hydrocortisone acetate 25 MG Rectal SuppositorySCD2
1291085hydrocortisone acetate 30 MG Rectal SuppositorySCD2

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
HYDROCORTISONE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
15bd4439-874a-4934-9954-248e5455d460Product name120260310
9962b773-9f2e-22cc-0032-535e48ac417bProduct name320250724
56bb0587-1bf2-48b2-9d93-fc9f59d1eeb2Product name120250325
4d56e8eb-d741-d4a5-de3f-2bab1af75a60Product name720220608
626d7260-31b5-4412-84fd-579746adb6b3Product name120210513
8a011600-5e61-4c59-ab7b-54ab658a3b71Product name220181127
a919621a-248d-3c7a-1084-9f9ce286fdfdProduct name220181009
e7d5a174-836b-a0af-b014-cb0826c69ddcProduct name220181004
fcce390d-6460-4701-87cf-940d8800a1c3Product name220180212
bf065fa6-1e3b-e4c3-0bde-2dc842ceeea1Product name220150218
02657a3f-1489-66ea-f740-5ab9524e57d7Product name120140508
26f3d783-2cc1-4327-e77d-71804cf675a2Product name120140508
36fdc54c-bbeb-981e-8a53-4d768e283892Product name120140508
58f3f9b7-3b9b-a9c1-1c9f-18ac777192b8Product name120140508
61e59a42-186b-9f4b-aec3-fb49a6debc31Product name120140508
705740e1-dee5-2610-c5a3-4c59cd9d62afProduct name120140508
7bdc4804-3832-c0df-e519-72b6d47c9792Product name120140508
a7051cba-790b-a699-81f8-dbbbdbd9b5acProduct name120140508
abaf203f-619e-f265-559f-8c81af5cb1c2Product name120140508
acc4d8bb-0e29-e9f8-65f8-31e94184a9c0Product name120140508
b045ad64-0f28-9a02-2f9b-b34d94fb2278Product name120140508
bfd28ffb-d550-3fe9-f65b-10bcb7f971fdProduct name120140508
da108d9e-edc8-17a3-8c28-3251c6a8acccProduct name120140508
fe21f3fd-a378-0654-1972-db3c3b64470eProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
24689-102-01Hydrocortisone Acetate12 in 1 CARTONSUPPOSITORY122
24689-103-01Hydrocortisone Acetate12 in 1 CARTONSUPPOSITORY122

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
24689-102HYDROCORTISONE ACETATE SUPPOSITORY [APNAR PHARMA LP]2Current NDC, Legacy NDC, 1 package rows20220318_cb60f2a6-8bab-c0f9-e053-2a95a90a422a.zip
24689-103HYDROCORTISONE ACETATE SUPPOSITORY [APNAR PHARMA LP]2Current NDC, Legacy NDC, 1 package rows20220318_cb60f2a6-8bab-c0f9-e053-2a95a90a422a.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
24689-102-01EA - Each24689-102fb04a74b-4ab1-450f-b8cb-1fc8e3647a0812022-07-06
24689-103-01EA - Each24689-10394185110-19ed-491a-b00a-eaee689bfc1512022-02-07

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 2 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
24689-10224689-102-01
24689-10324689-103-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 2 matching rows.

Name, UNII, Kind table
NameUNIIKind
HYDROCORTISONE ACETATE3X7931PO74ACTIB
HYDROCORTISONE ACETATE3X7931PO74ACTIB

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Hydrocortisone AcetateHYDROCORTISONE ACETATEAPNAR PHARMA LPcb60f2a6-8bab-c0f9-e053-2a95a90a422a2022-03-16Adverse reactionsExact identifier
ndc (package): 24689-103-01
ndc (package): 24689-102-01
ndc (product): 24689-102
ndc (product): 24689-103
ndc11 (package): 24689010201
ndc11 (package): 24689010301
spl id: da4ff888-1b0c-8c8b-e053-2995a90a13fa
spl set id: cb60f2a6-8bab-c0f9-e053-2a95a90a422a

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.